Imatinib Clinical Trials

• Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
  ClinicalTrials.gov Identifier: NCT00297570 - Recruiting
  Leukemia, Myeloid, Philadelphia-Positive
  
• Safety and Efficacy of Imatinib in Dermatofibrosarcoma Protuberans (DFSP)
  ClinicalTrials.gov Identifier: NCT00122473 - Active, not recruiting
  Dermatofibrosarcoma
  
• Phase 2 Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive ALL
  ClinicalTrials.gov Identifier: NCT00130195 - Active, not recruiting
  Acute Lymphoblastic Leukemia
  
• Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly with Imatinib Mesylate (STI571) and Chemotherapy.
  ClinicalTrials.gov Identifier: NCT00149136 - Active, not recruiting
  Acute Lymphocytic Leukemia
  
• Imatinib (Gleevec® (Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00076297 - Recruiting
  
  
• Imatinib Mesylate in Treating Patients With Gliomas
  ClinicalTrials.gov Identifier: NCT00039364 - Active, not recruiting
  adult brain tumor
  
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
  ClinicalTrials.gov Identifier: NCT00362466 - Recruiting
  Leukemia
  
• Efficacy and Safety of Imatinib in Chordoma
  ClinicalTrials.gov Identifier: NCT00150072 - Recruiting
  Chordoma
  
• Imatinib Mesylate, Interferon Alfa, and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00363649 - Recruiting
  Leukemia
  
• Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate
  ClinicalTrials.gov Identifier: NCT00510354 - Recruiting
  Progressive Gastrointestinal Stromal Tumor
  
• AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
  ClinicalTrials.gov Identifier: NCT00146913 - Active, not recruiting
  Chronic Myeloid Leukemia
  
• Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
  ClinicalTrials.gov Identifier: NCT00025246 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery
  ClinicalTrials.gov Identifier: NCT00041197 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Phase II Study of Hyper-CVAD plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00038610 - Active, not recruiting
  Leukemia, Lymphocytic, Acute, L2
  
• Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00091078 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib
  ClinicalTrials.gov Identifier: NCT00461929 - Recruiting
  Chronic Myeloid Leukemia; Gastrointestinal Stromal Cell Tumors; Chromosome Abnormality
  
• Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
  ClinicalTrials.gov Identifier: NCT00062205 - Active, not recruiting
  recurrent tumors of the Ewing's family
  
• BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
  ClinicalTrials.gov Identifier: NCT00112775 - Active, not recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia; relapsing chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00090987 - Active, not recruiting
  epidemic Kaposi's sarcoma; recurrent Kaposi's sarcoma
  
• Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Carcinosarcoma
  ClinicalTrials.gov Identifier: NCT00075400 - Active, not recruiting
  uterine carcinosarcoma; recurrent uterine sarcoma
  
• Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
  ClinicalTrials.gov Identifier: NCT00327262 - Recruiting
  Chronic Myeloid Leukemia
  
• Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00028002 - Active, not recruiting
  gastrointestinal stromal tumor
  
• Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/neu-Expressing Cancer
  ClinicalTrials.gov Identifier: NCT00084513 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00087152 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
  ClinicalTrials.gov Identifier: NCT00264160 - Recruiting
  Chronic Mylogenous Leukemia (CML) Patients Resistant or Intolerant to Imatinib Mesylate Therapy
  
• Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00041041 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome
  ClinicalTrials.gov Identifier: NCT00044304 - Recruiting
  Hypereosinophilic Syndrome
  
• Imatinib Mesylate in Treating Patients With Myelofibrosis
  ClinicalTrials.gov Identifier: NCT00039416 - Active, not recruiting
  Polycythemia Vera; chronic idiopathic myelofibrosis; Essential Thrombocythemia; Chronic Myelomonocytic Leukemia
  
• Study Comparing 12 Months versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
  ClinicalTrials.gov Identifier: NCT00116935 - Recruiting
  Sarcoma; Gastrointestinal Stromal Tumor
  
• Imatinib Mesylate in Treating Patients With Myelofibrosis
  ClinicalTrials.gov Identifier: NCT00245128 - Active, not recruiting
  Chronic Myeloproliferative Disorders
  
• Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
  ClinicalTrials.gov Identifier: NCT00420043 - Active, not recruiting
  Healthy
  
• Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
  ClinicalTrials.gov Identifier: NCT00193258 - Active, not recruiting
  Prostate Cancer
  
• Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00103168 - Recruiting
  gastrointestinal stromal tumor
  
• Phase II: Imatinib & Gemcitabine for First-Line Tx of Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00161213 - Recruiting
  Pancreatic Cancer
  
• Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
  ClinicalTrials.gov Identifier: NCT00080678 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer; bone metastases
  
• AG-858 and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Were Previously Treated With Imatinib Mesylate
  ClinicalTrials.gov Identifier: NCT00070395 - Recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00028847 - Active, not recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
  ClinicalTrials.gov Identifier: NCT00030667 - Active, not recruiting
  Ewing's family of tumors; childhood soft tissue sarcoma; Gastrointestinal Cancer; metastatic cancer; Neuroblastoma; Osteosarcoma
  
• Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
  ClinicalTrials.gov Identifier: NCT00112632 - Recruiting
  gastrointestinal stromal tumor
  
• Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00052494 - Active, not recruiting
  extensive stage small cell lung cancer; Recurrent Small Cell Lung Cancer
  
• Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00080665 - Active, not recruiting
  Male Breast Cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; recurrent breast cancer
  
• Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00053248 - Active, not recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma
  ClinicalTrials.gov Identifier: NCT00085475 - Active, not recruiting
  recurrent adult soft tissue sarcoma; stage III adult soft tissue sarcoma; stage IV adult soft tissue sarcoma; adult fibrosarcoma; ...
  
• Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
  ClinicalTrials.gov Identifier: NCT00354523 - Active, not recruiting
  Solid Tumor; Thyroid Cancer
  
• Oblimersen Plus Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00049192 - Active, not recruiting
  Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; relapsing chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Refractory Metastatic and/or Unresectable Stomach or Gastroesophageal Junction Cancer
  ClinicalTrials.gov Identifier: NCT00068380 - Active, not recruiting
  recurrent gastric cancer; stage IV gastric cancer; recurrent esophageal cancer; stage IV esophageal cancer; stage III esophageal cancer; ...
  
• Hormonal Ablation, Imatinib & Docetaxel Followed by Radical Prostatectomy for High-Risk Localized Prostate Ca.
  ClinicalTrials.gov Identifier: NCT00500110 - Active, not recruiting
  Prostate Cancer
  
• Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans (DFSP) or Transformed Fibrosarcomatous DFSP
  ClinicalTrials.gov Identifier: NCT00084630 - Active, not recruiting
  adult fibrosarcoma; recurrent adult soft tissue sarcoma; stage III adult soft tissue sarcoma; adult malignant fibrous histiocytoma; ...
  
• Interferon alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00045422 - Active, not recruiting
  Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; childhood chronic myelogenous leukemia
  
• Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
  ClinicalTrials.gov Identifier: NCT00045669 - Active, not recruiting
  recurrent salivary gland cancer; salivary gland adenoid cystic carcinoma; stage III salivary gland cancer; stage IV salivary gland cancer
  
• Open-Label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
  ClinicalTrials.gov Identifier: NCT00171938 - Active, not recruiting
  Glioblastoma
  
• Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00036751 - Active, not recruiting
  stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00248482 - Active, not recruiting
  Lung Cancer
  
• Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00301093 - Active, not recruiting
  Leukemia
  
• Imatinib Mesylate in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00324636 - Active, not recruiting
  Leukemia
  
• Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
  ClinicalTrials.gov Identifier: NCT00441155 - Active, not recruiting
  Gastrointestinal Stromal Tumors
  
• Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
  ClinicalTrials.gov Identifier: NCT00314873 - Active, not recruiting
  Thymic Carcinoma
  
• Registration of Children With CML and Treatment With Imatinib
  ClinicalTrials.gov Identifier: NCT00445822 - Recruiting
  Myeloid Leukemia, Chronic
  
• Imatinib Mesylate, Busulfan, Fludarabine, and ATG for CML Patients
  ClinicalTrials.gov Identifier: NCT00499889 - Recruiting
  Leukemia
  
• Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
  ClinicalTrials.gov Identifier: NCT00021229 - Active, not recruiting
  childhood central nervous system germ cell tumor; high-grade childhood cerebral astrocytoma; untreated childhood brain stem glioma; ...
  
• Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
  ClinicalTrials.gov Identifier: NCT00287846 - Recruiting
  Desmoid Tumor
  
• Interleukin 11, Thrombocytopenia, CML, Imatinib in CML Patients
  ClinicalTrials.gov Identifier: NCT00493181 - Active, not recruiting
  Leukemia; Chronic Myelogenous Leukemia; CML
  
• Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
  ClinicalTrials.gov Identifier: NCT00171977 - Active, not recruiting
  Gastrointestinal Stromal Tumors
  
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00333840 - Active, not recruiting
  Chronic Myelogenous Leukemia
  
• Expanded Access Program of AMN107 in Imatinib-Resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00302016 - Active, not recruiting
  Chronic Myeloid Leukemia
  
• Phase I Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With AICP
  ClinicalTrials.gov Identifier: NCT00424385 - Recruiting
  Prostate Cancer
  
• SU011248 in Patients with Malignant Gastrointestinal Stromal Tumor (GIST) That Have Progressed During or Not Tolerated Treatment with Imatinib Mesylate (GLEEVEC™)
  ClinicalTrials.gov Identifier: NCT00075218 - Active, not recruiting
  Gastrointestinal Neoplasms
  
• An Extension Study of the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis
  ClinicalTrials.gov Identifier: NCT00171158 - Active, not recruiting
  Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis
  
• Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
  ClinicalTrials.gov Identifier: NCT00354068 - Recruiting
  Brain and Central Nervous System Tumors
  
• Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
  ClinicalTrials.gov Identifier: NCT00500188 - Recruiting
  Gastrointestinal Stromal Tumors
  
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
  ClinicalTrials.gov Identifier: NCT00354913 - Recruiting
  Brain and Central Nervous System Tumors
  
• An Extension Study of the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia
  ClinicalTrials.gov Identifier: NCT00171223 - Active, not recruiting
  Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
  
• An Extension Study of the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia
  ClinicalTrials.gov Identifier: NCT00171249 - Active, not recruiting
  Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
  
• Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
  ClinicalTrials.gov Identifier: NCT00401024 - Recruiting
  Brain and Central Nervous System Tumors
  
• CCI-779 and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00101088 - Recruiting
  accelerated phase chronic myelogenous leukemia; blastic phase chronic myelogenous leukemia; ...
  
• Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
  ClinicalTrials.gov Identifier: NCT00049127 - Recruiting
  adult anaplastic oligodendroglioma; recurrent adult brain tumor; Mixed Gliomas; Adult Oligodendroglioma
  
• Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
  ClinicalTrials.gov Identifier: NCT00290771 - Active, not recruiting
  Recurrent Glioblastoma Multiforme (GBM)
  
• Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
  ClinicalTrials.gov Identifier: NCT00292149 - Active, not recruiting
  Recurrent Glioblastoma Multiforme (GBM)
  
• Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00070499 - Recruiting
  chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia
  
• Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
  ClinicalTrials.gov Identifier: NCT00387933 - Recruiting
  Brain and Central Nervous System Tumors
  
• Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
  ClinicalTrials.gov Identifier: NCT00471328 - Recruiting
  Gastrointestinal Stromal Tumors
  
• Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
  ClinicalTrials.gov Identifier: NCT00390897 - Active, not recruiting
  Chronic Myeloid Leukaemia
  
• An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
  ClinicalTrials.gov Identifier: NCT00538109 - Active, not recruiting
  Leukemia, Myeloid, Chronic
  
• Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
  ClinicalTrials.gov Identifier: NCT00039377 - Recruiting
  adult acute lymphoblastic leukemia in remission
  
• Trial of Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients
  ClinicalTrials.gov Identifier: NCT00402766 - Recruiting
  Mesothelioma
  
• Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00268229 - Recruiting
  Leukemia
  
• Imatinib in Adult Patients With Metastatic Ocular Melanoma
  ClinicalTrials.gov Identifier: NCT00421317 - Recruiting
  Melanoma
  
• Efficacy, Safety and Long-Term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
  ClinicalTrials.gov Identifier: NCT00237120 - Active, not recruiting
  Chronic Myelogenous Leukemia in Chronic Phase
  
• Efficacy and Safety of AMN107 (Nilotinib)Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension
  ClinicalTrials.gov Identifier: NCT00488150 - Recruiting
  Gastrointestinal Stromal Tumors
  
• Study of Dasatinib in Patients With Chronic Phase CML and a Suboptimal Response to Imatinib
  ClinicalTrials.gov Identifier: NCT00320190 - Recruiting
  Leukemia, Myeloid, Chronic
  
• Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
  ClinicalTrials.gov Identifier: NCT00509093 - Recruiting
  Leukemia
  
• Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00219726 - Recruiting
  Chronic Myeloid Leukemia
  
• PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
  ClinicalTrials.gov Identifier: NCT00335868 - Recruiting
  Leukemia
  
• Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
  ClinicalTrials.gov Identifier: NCT00171912 - Recruiting
  Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
  
• Combination Chemotherapy With or Without Imatinib Mesylate and/or Peripheral Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
  ClinicalTrials.gov Identifier: NCT00458848 - Recruiting
  Leukemia
  
• A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
  ClinicalTrials.gov Identifier: NCT00570635 - Recruiting
  Gastrointestinal Stromal Tumors; Gastrointestinal Neoplasms
  
• Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
  ClinicalTrials.gov Identifier: NCT00074308 - Recruiting
  stage III melanoma; Stage IV Melanoma; Recurrent Melanoma; unspecified adult solid tumor, protocol specific
  
• Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00483366 - Recruiting
  Unspecified Adult Solid Tumor, Protocol Specific
  
• Imatinib Mesylate, Bevacizumab, and Cyclophosphamide in Treating Patients With Refractory Metastatic Solid Tumors
  ClinicalTrials.gov Identifier: NCT00390156 - Recruiting
  Unspecified Adult Solid Tumor, Protocol Specific
  
• Imatinib in Systemic Sclerosis
  ClinicalTrials.gov Identifier: NCT00506831 - Recruiting
  Scleroderma, Systemic